<DOC>
	<DOCNO>NCT00489164</DOCNO>
	<brief_summary>The main objective study assess in-stent late lumen loss diabetic patient de novo native coronary lesion use sirolimus-eluting Bx VELOCITYÃ¤ stent compare Bx VELOCITY balloon-expandable stent .</brief_summary>
	<brief_title>Feasibility Study With Sirolimus-Eluting BX Velocity Balloon-Expandable Stent Treatment Diabetic Patients With Native Coronary Artery Lesions</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient must 18 year age ; 2 . Patients must previously diagnose Type I Type II diabetes document treatment insulin oral hypoglycemics medical history . ( Undocumented newly diagnose diabetic must fast plasma glucose &gt; /= 126 mg/dl 2h postload value OGTT &gt; /=200 mg/dl , confirm alternate day ) ; 3 . Female childbearing potential must negative pregnancy test must plan accept method contraception 6 month time enrollment ; 4 . Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , IIIIII ) OR patient document silent ischemia ; 5 . Treatment lesion native coronary artery require maximum three stent per patient . Multivessel treatment permissible . Additional stent may use procedural complication dissection . Patients additional lesion include lesion consider clinically significant require treatment ; 6 . Target lesion &gt; /=2.25 &lt; /=3.0 diameter ( visual estimate ) ; 7 . Individual lesion &gt; /=10 mm &lt; /= 32 mm length locate native coronary artery ; 8 . Target lesion de novo lesion native coronary vessel ; 9 . Acceptable candidate coronary artery bypass surgery ( CABG ) ; 10 . Target lesion stenosis &gt; 50 % &lt; 100 % ( TIMI I ) ( visual estimate ) ; 11 . Patient willing comply specify followup evaluation ; 12 . Patient must provide write informed consent prior procedure use form approve local Institutional Review Board . 1 . Patient experience Qwave nonQwave myocardial infarction document total CK &gt; 2 time normal within precede 24 hour CK CKMB enzymes remain normal time treatment ; 2 . Unprotected leave main coronary disease 50 % stenosis ; 3 . Significant ( &gt; /=50 % ) stenoses proximal distal target lesion might require revascularization impede runoff ; 4 . Patients admit treatment diabetic ketoacidosis &gt; /= 2 time past six month ( Brittle Diabetics ) ; 5 . Intervention another lesion occur within six month prior index procedure ; 6 . Have ostial target lesion ; 7 . Target lesion saphenous venous graft . 8 . Target lesion due instent restenosis . 9 . Angiographic evidence thrombus within target lesion ; 10 . Calcified lesion successfully predilated ; 11 . Ejection fraction &lt; /=30 % ; 12 . Totally occluded vessel ( TIMI 0 level ) ; 13 . Impaired renal function ( creatinine &gt; 2.0 mg/dL ) ; 14 . Target lesion excessive tortuosity unsuitable stent delivery deployment ; 15 . Pretreatment device balloon angioplasty ( direct stenting allow ) ; 16 . Target lesion involve bifurcation include side branch &gt; /=2.5mm diameter ( either stenosis main vessel major branch stenosis major branch ) would require side branch stenting likely occur side branch diseased intend stented ; 17 . Previous brachytherapy target vessel ; 18 . Recipient heart transplant ; 19 . Patient life expectancy le 12 month ; 20 . Known allergy aspirin , clopidogrel bisulfate ( Plavix ) ticlopidine ( Ticlid ) , heparin , stainless steel , contrast agent sirolimus , medically manage ; 21 . Any significant medical condition investigator 's opinion may interfere patient 's optimal participation study ; 22 . Currently participate investigational drug another device study ; 23 . Treatment Metformin ( glucophage ) within 48 hour angiogram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>DIABETIC PATIENTS WITH NATIVE CORONARY ARTERY LESIONS</keyword>
</DOC>